Work

Recombinant desulfatohirudin as a substitute for heparin during cardiopulmonary bypass*Supported by grant HL 19055 from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md

Year: 1994

Type: article

Abstract: Despite large doses of heparin sufficient to maintain activated clotting times greater than 400 seconds, thrombin is produced during cardiopulmonary bypass. Both the prothrombin fragment, F1.2, and the fibrinogen fragment, fibrinopeptide A (FPA), increase progressively during bypass.1, 2 Thrombin is a powerful protease that converts fibrinogen to fibrin but also activates platelets, induces endothelial cells to release tissue plasminogen activator, and contributes importantly to bleeding and thromboembolic complications associated with cardiac operations.

Source: Journal of Thoracic and Cardiovascular Surgery

DOI: 10.1016/s0022-5223(94)70022-2

Authors: A. Bernabei, A.K. Rao, S. Niewiarowski, R.W. Colman, L. Sun, L.H. Edmunds

Institutions: University of Pennsylvania, Temple University

Language: English

Topic: Cardiac and Coronary Surgery Techniques

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,500